Asymmetric Dimethylarginine as a Biomarker in Coronary Artery Disease

Author:

Theofilis Panagiotis1,Papageorgiou Nikolaos2,Oikonomou Evangelos13,Lazaros George1,Sagris Marios1,Tousoulis Dimitris1

Affiliation:

1. 1st Cardiology Department, Hippokration General Hospital, University of Athens Medical School, Athens, Greece

2. Electrophysiology Department, Barts Heart Centre, St. Bartholomew's Hospital, West Smithfield, London, UK

3. 3rd Cardiology Department, Sotiria Regional Hospital for Chest Diseases, University of Athens Medical School, Athens, Greece

Abstract

Abstract: As atherosclerosis remains a leading cause of morbidity and mortality worldwide despite the advances in its medical and interventional management, the identification of markers associated with its incidence and prognosis constitutes an appealing prospect. In this regard, asymmetric dime-thylarginine (ADMA), a well-studied endogenous endothelial nitric oxide synthase inhibitor, repre-sents a core mediator of endothelial dysfunction in atherosclerotic diseases. Given the pathophysio-logic background of this molecule, its importance in the most frequent atherosclerotic manifesta-tion, coronary artery disease (CAD), has been extensively studied in the past decades. The available evidence suggests elevation of ADMA in the presence of common cardiovascular risk factors, namely diabetes mellitus, arterial hypertension, and hypertriglyceridemia, being related to endothe-lial dysfunction and incident major adverse cardiovascular events in these groups of patients. More-over, ADMA is associated with CAD occurrence and severity, as well as its prognosis, especially in populations with renal impairment. Interestingly, even in the absence of obstructive CAD, increased ADMA may indicate coronary endothelial dysfunction and epicardial vasomotor dysfunction, which are prognostication markers for incident cardiovascular events. In the case of acute coronary syn-dromes, high ADMA levels signify an augmented risk of incomplete ST-segment elevation resolu-tion and poorer prognosis. Abnormal ADMA elevations may indicate adverse outcomes following percutaneous or surgical coronary revascularization, such as in-stent restenosis, graft patency, and hard cardiovascular endpoints. Finally, since its association with inflammation is significant, chron-ic inflammatory conditions may present with coronary endothelial dysfunction and subclinical cor-onary atherosclerosis by means of increased coronary artery calcium, with augmented ADMA act-ing as a biomarker.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference101 articles.

1. Tsao C.W.; Aday A.W.; Almarzooq Z.I.; Alonso A.; Beaton A.Z.; Bittencourt M.S.; Boehme A.K.; Buxton A.E.; Carson A.P.; Commodore-Mensah Y.; Elkind M.S.V.; Evenson K.R.; Eze-Nliam C.; Ferguson J.F.; Generoso G.; Ho J.E.; Kalani R.; Khan S.S.; Kissela B.M.; Knutson K.L.; Levine D.A.; Lewis T.T.; Liu J.; Loop M.S.; Ma J.; Mussolino M.E.; Navaneethan S.D.; Perak A.M.; Poudel R.; Rezk-Hanna M.; Roth G.A.; Schroeder E.B.; Shah S.H.; Thacker E.L.; VanWagner L.B.; Virani S.S.; Voecks J.H.; Wang N.Y.; Yaffe K.; Martin S.S.; Heart disease and stroke statistics-2022 update: A report from the American Heart Association. Circulation 2022,145(8),e153-e639

2. Theofilis P.; Sagris M.; Oikonomou E.; Antonopoulos A.S.; Siasos G.; Tsioufis K.; Tousoulis D.; Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Res Clin Pract 2022,188

3. Theofilis P.; Antonopoulos A.S.; Katsimichas T.; Oikonomou E.; Siasos G.; Aggeli C.; Tsioufis K.; Tousoulis D.; The impact of SGLT2 inhibition on imaging markers of cardiac function: A systematic review and meta-analysis. Pharmacol Res 2022,180

4. Sagris M.; Theofilis P.; Antonopoulos A.S.; Oikonomou E.; Paschaliori C.; Galiatsatos N.; Tsioufis K.; Tousoulis D.; Inflammation in coronary microvascular dysfunction. Int J Mol Sci 2021,22(24),13471

5. Sagris M.; Theofilis P.; Antonopoulos A.S.; Tsioufis C.; Oikonomou E.; Antoniades C.; Crea F.; Kaski J.C.; Tousoulis D.; Inflammatory mechanisms in COVID-19 and atherosclerosis: Current pharmaceutical perspectives. Int J Mol Sci 2021,22(12),6607

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3